Idorsia Ltd (IDRSF)
USD 1.0
(0.0%)
USD 1.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -297.92 Million CHF | 64.01% |
| 2022 | -827.89 Million CHF | -30.46% |
| 2021 | -634.59 Million CHF | -42.67% |
| 2020 | -444.79 Million CHF | 9.89% |
| 2019 | -493.6 Million CHF | -27.75% |
| 2018 | -386.39 Million CHF | -2607.9% |
| 2017 | -14.26 Million CHF | 95.74% |
| 2016 | -335.14 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 29.86 Million CHF | 125.59% |
| 2024 Q2 | -108.57 Million CHF | -463.61% |
| 2023 Q1 | -212.18 Million CHF | -10.05% |
| 2023 Q3 | 224.04 Million CHF | 216.02% |
| 2023 Q2 | -193.11 Million CHF | 8.99% |
| 2023 FY | -297.92 Million CHF | 64.01% |
| 2023 Q4 | -116.67 Million CHF | -152.08% |
| 2022 FY | -827.89 Million CHF | -30.46% |
| 2022 Q4 | -192.81 Million CHF | 10.71% |
| 2022 Q3 | -215.95 Million CHF | 2.54% |
| 2022 Q2 | -221.57 Million CHF | -12.16% |
| 2022 Q1 | -197.55 Million CHF | 21.49% |
| 2021 Q3 | -139.58 Million CHF | -0.54% |
| 2021 Q1 | -104.53 Million CHF | 23.68% |
| 2021 Q2 | -138.83 Million CHF | -32.82% |
| 2021 FY | -634.59 Million CHF | -42.67% |
| 2021 Q4 | -251.64 Million CHF | -80.28% |
| 2020 Q4 | -136.96 Million CHF | -15.6% |
| 2020 Q2 | -69.31 Million CHF | 42.25% |
| 2020 Q1 | -120.03 Million CHF | 15.33% |
| 2020 Q3 | -118.48 Million CHF | -70.93% |
| 2020 FY | -444.79 Million CHF | 9.89% |
| 2019 Q2 | -125.55 Million CHF | -18.0% |
| 2019 FY | -493.6 Million CHF | -27.75% |
| 2019 Q4 | -141.76 Million CHF | -18.24% |
| 2019 Q3 | -119.88 Million CHF | 4.51% |
| 2019 Q1 | -106.4 Million CHF | 1.69% |
| 2018 Q3 | -119.12 Million CHF | -48.1% |
| 2018 FY | -386.39 Million CHF | -2607.9% |
| 2018 Q4 | -108.23 Million CHF | 9.14% |
| 2018 Q2 | -80.43 Million CHF | -2.32% |
| 2018 Q1 | -78.6 Million CHF | -221.0% |
| 2017 Q2 | 103.39 Million CHF | 190.16% |
| 2017 Q3 | -70.8 Million CHF | -168.48% |
| 2017 Q4 | 64.96 Million CHF | 191.75% |
| 2017 Q1 | -114.67 Million CHF | 0.0% |
| 2017 FY | -14.26 Million CHF | 95.74% |
| 2016 FY | -335.14 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | -9293.883% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -7929.709% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -12413.115% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 662.338% |
| GB Sciences, Inc. | -1.36 Million USD | -21778.977% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -9744.934% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -130494.362% |
| Skye Bioscience, Inc. | -37.64 Million USD | -691.4% |
| Zenith Capital Corp. | -10.59 Million USD | -2711.636% |
| Agentix Corp. | -1.37 Million USD | -21579.422% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -4166.476% |
| Biomind Labs Inc. | -1.21 Million USD | -24433.998% |
| ContraFect Corporation | -65.15 Million USD | -357.264% |
| CSL Limited | 2.64 Billion USD | 111.276% |
| CytoDyn Inc. | -49.84 Million USD | -497.743% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -15183.886% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -47009.061% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -375.92% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -71605.429% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -16264.538% |
| Regen BioPharma, Inc. | 1.02 Million USD | 29207.833% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 557.405% |
| SQZ Biotechnologies Company | -79.46 Million USD | -274.913% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -13630.255% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -297.424% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -10200.153% |
| Mesoblast Limited | -87.95 Million USD | -238.716% |
| Marizyme, Inc. | -65.34 Million USD | -355.907% |
| Genus plc | 7.9 Million USD | 3871.152% |
| Pharming Group N.V. | -10.54 Million USD | -2724.431% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -3268.623% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -17146.238% |
| IMV Inc. | -36.48 Million USD | -716.542% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -3596.436% |
| MultiCell Technologies, Inc. | -380.07 USD | -78385723.664% |
| ONE Bio Corp. | 8.67 Million USD | 3533.61% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -476.339% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -7880.739% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -9504.877% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -3669.676% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -1989222.917% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -1777.088% |
| Alpha Cognition Inc. | -13.77 Million USD | -2063.148% |
| Enzolytics Inc. | -2.17 Million USD | -13585.99% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | -0.972% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 304101.02% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 4402.361% |
| Genscript Biotech Corporation | -95.47 Million USD | -212.034% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -4430.352% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -108868.113% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -7085.856% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -492815.277% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -14758.051% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -2635.293% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -5997.363% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -7852.154% |
| Helix BioMedix, Inc. | -1.05 Million USD | -28110.693% |
| EV Biologics, Inc. | -1.26 Million USD | -23411.404% |
| Q BioMed Inc. | -2.05 Million USD | -14417.909% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -7701.021% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -398.818% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -3411.984% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -5021.335% |
| HST Global, Inc. | -146.21 Thousand USD | -203662.397% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -22208.977% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -16877.771% |
| Halberd Corporation | -79.67 Thousand USD | -373815.608% |
| Resverlogix Corp. | -3.61 Million USD | -8152.659% |
| Cell Source, Inc. | -5.32 Million USD | -5498.743% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -7398.654% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | -4545.11% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -1281721.702% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -6146.788% |
| Kadimastem Ltd | -3.3 Million USD | -8907.715% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -6606.104% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -67399.303% |
| LadRx Corporation | 400.44 Thousand USD | 74497.854% |
| Regen BioPharma, Inc. | 1.02 Million USD | 29207.833% |
| Affymax, Inc. | -14.42 Million USD | -1965.453% |
| Itoco Inc. | -1.86 Million USD | -15840.171% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -17750.27% |
| Mobile Lads Corp. | -2.26 Million USD | -13063.171% |
| International Stem Cell Corporation | -131 Thousand USD | -227320.611% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | -6860.768% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -376857.727% |
| Qrons Inc. | -789.34 Thousand USD | -37642.716% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -31542.254% |
| SYBLEU INC | -180.3 Thousand USD | -165132.607% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -14170.42% |
| Rebus Holdings, Inc. | -1.02 Million USD | -29107.941% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -18373.006% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -548840.522% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -11674.384% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -519.739% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -13992.763% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -38051.615% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -9304.072% |
| Neutra Corp. | -233.46 Thousand USD | -127508.421% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -1368.242% |
| PureTech Health plc | -65.69 Million USD | -353.477% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -1300.891% |
| IXICO plc | -1.17 Million USD | -25190.407% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -2901.118% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -421.497% |
| CSL Limited | 2.64 Billion USD | 111.276% |
| Cellectis S.A. | -103.17 Million USD | -188.756% |